Alzheon
Alzheon: A Framingham-based biopharmaceutical firm developing treatments for neurological disorders.
Founded
2013Alzheon: A Framingham-based biopharmaceutical firm developing treatments for neurological disorders.
Founded in 2013, Alzheon is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. The company's core mission is to develop innovative treatments for Alzheimer's disease and other neurological and psychiatric disorders. Alzheon leverages precision medicine to create solutions that can significantly slow or halt the progression of these diseases. Their leading product, ALZ-801, is an oral anti-amyloid treatment currently in Phase testing, aimed at preventing the onset of clinical symptoms and preserving future memories.
Key figures in Alzheon include CEO Martin Tolar, MD, PhD, and Executive Chairman Neil Flanzraich. The company has garnered attention for its significant advancements in Alzheimer's research, particularly with ALZ-801. By focusing on well-tolerated treatments based on extensive research, Alzheon has made impactful strides in the pharmaceutical industry, offering hope to millions affected by neurological disorders. Their work has positioned them as a promising player in the fight against Alzheimer's disease.
Companies similar to Alzheon include Allyx Therapeutics, Aztherapies, Alzeca Biosciences and Alkeus Pharmaceuticals.
Alzheon was founded in 2013.
Alzheon's headquarters is located in Framingham, MA, US.
Alzheon's most recent funding round was for $1.7M (USD) in January 2023.
As of Jan 11, 2023, Alzheon has disclosed funding of $140M (USD). Undisclosed round amounts are excluded.
Alzheon has 11 employees as of Feb 5, 2024.
Alkeus Pharmaceuticals
alkeus.com
